NYSE:AGE AgeX Therapeutics (AGE) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free AGE Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range$0.22▼$16.5152-Week Range N/AVolume3,700 shsAverage Volume3,849 shsMarket Capitalization$11.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial MediaStock AnalysisChartEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial Media Get AgeX Therapeutics alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About AgeX Therapeutics Stock (NYSE:AGE)AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.Read More Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. AGE Stock News HeadlinesApril 23, 2024 | americanbankingnews.comAgeX Therapeutics (NYSE:AGE) Trading Down 11.9%March 26, 2024 | globenewswire.comSerina Therapeutics Announces Completion of Merger with AgeX TherapeuticsApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 23, 2024 | finanznachrichten.deAgeX Therapeutics, Inc.: AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial ResultsMarch 22, 2024 | globenewswire.comAgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial ResultsFebruary 27, 2024 | businesswire.comAGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGEFebruary 7, 2024 | msn.comAgeX Therapeutics Secures $500K Convertible Note DealFebruary 7, 2024 | msn.comAgeX Therapeutics Expands Ties with JuvVentures Equity DealApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.January 25, 2024 | msn.comWhy IBM Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving PremarketDecember 13, 2023 | morningstar.comAgeX Therapeutics Inc AGENovember 17, 2023 | msn.comWhat's Going On With Penny Stock AgeX Therapeutics?November 17, 2023 | finance.yahoo.comSerina Therapeutics Announces POZ Polymer Technology License Agreement with PfizerNovember 14, 2023 | msn.comAgeX Therapeutics GAAP EPS of -$0.14, revenue of $0.06MNovember 14, 2023 | finance.yahoo.comAgeX Therapeutics Reports Third Quarter 2023 Financial ResultsNovember 6, 2023 | benzinga.comObesity Pipeline | Clinical Trials, Key Companies – Aardvark, Adocia, Agentix AgeX TherapeuticsAugust 31, 2023 | msn.comSerina Therapeutics to merge with subsidiary of AgeXAugust 30, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether AgeX Therapeutics, Inc. has obtained a Fair Price in its transaction with SerinaAugust 30, 2023 | seekingalpha.comSerina Therapeutics and Agex Therapeutics enter merger agreementAugust 30, 2023 | marketwatch.comAgeX Therapeutics Shares Rise Premarket on Reverse Merger Deal >AGEAugust 30, 2023 | finance.yahoo.comSerina Therapeutics and AgeX Therapeutics Enter into Merger AgreementAugust 14, 2023 | finance.yahoo.comAgeX Therapeutics Reports Second Quarter 2023 Financial ResultsJuly 24, 2023 | finance.yahoo.comAgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred StockJuly 21, 2023 | seekingalpha.comAgeX issues preferred stock to Juvenescence to nix $36M debtJune 28, 2023 | finance.yahoo.com25 States with the Highest Life Expectancy in the USMay 17, 2023 | finance.yahoo.comNYSE American to Suspend Trading Immediately in AgeX Therapeutics, Inc. (AGE) and Commence Delisting ProceedingsMay 17, 2023 | businesswire.comCORRECTING and REPLACING NYSE American to Commence Delisting Proceedings Against AgeX Therapeutics, Inc. (AGE)See More Headlines Receive AGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AgeX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:AGE CUSIPN/A CIK1708599 Webwww.agexinc.com Phone(510) 671-8370Fax510-871-4154Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($13.0282) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,800,000.00 Net Margins-10,424.65% Pretax Margin-10,430.28% Return on EquityN/A Return on Assets-120.90% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.36 Sales & Book Value Annual Sales$140,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($16.07) per share Price / BookN/AMiscellaneous Outstanding Shares1,080,000Free Float1,008,000Market Cap$11.99 million OptionableNot Optionable Beta1.18 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Joanne M. Hackett Ph.D. (Age 46)Interim CEO & Chairman of the Board Comp: $55.74kMs. Eun-Jae Park CPA (Age 52)Chief Financial Officer Comp: $295.29kDr. Ivan LabatChief Information OfficerMs. Judith Segall (Age 71)Secretary Key CompetitorsPurple BiotechNASDAQ:PPBTImunonNASDAQ:IMNNMonopar TherapeuticsNASDAQ:MNPRRedHill BiopharmaNASDAQ:RDHLMIRA PharmaceuticalsNASDAQ:MIRAView All CompetitorsInstitutional OwnershipSigma Planning CorpBought 105,040 shares on 2/1/2024Ownership: 0.755%View All Institutional Transactions AGE Stock Analysis - Frequently Asked Questions When is AgeX Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our AGE earnings forecast. When did AgeX Therapeutics' stock split? Shares of AgeX Therapeutics split on Monday, March 18th 2024. The 8-5 split was announced on Monday, March 18th 2024. The newly minted shares were issued to shareholders after the closing bell on Monday, March 18th 2024. An investor that had 100 shares of stock prior to the split would have 160 shares after the split. What other stocks do shareholders of AgeX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other AgeX Therapeutics investors own include Biocept (BIOC), Allena Pharmaceuticals (ALNA), Co-Diagnostics (CODX), Moleculin Biotech (MBRX), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), AIM ImmunoTech (AIM), AzurRx BioPharma (AZRX) and Digital Ally (DGLY). How do I buy shares of AgeX Therapeutics? Shares of AGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:AGE) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AgeX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
